Entity

KRAS

A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.

As of 3 Nov 2026Last evidence 2 Nov 2026

What is happening now

  • Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer - Oncodaily

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher

  • KRAS in pancreatic cancer: from molecular biology to transformative therapeutics

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

All 2 events and claims involving KRAS

What changed

  • Attention Fading: 9 mentions on 2 Nov 2026, against 23 on 11 Oct 2026 (-61%).
  • State No change in coverage state or wire tier recorded since 21 Oct 2026.
  • Claims No claim first reported since 2 Nov 2026.

How well we know this

515 documents · 184 publishers · 8% contain a typed assertion · last evidence 2 Nov 2026

  • Gap: assertion coverage 0.078: about 92% of mentions carry no typed assertion
  • Gap: 6 receipts withheld: no source link (the same rule the topic record applies)

In this snapshot’s daily coverage:

Reported alongside KRAS

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Lung CancerImmunotherapyEgfrBraf
  • Colorectal Cancer · 178 shared documents · no page of its own yet
  • Lung Cancer · 131 shared documents
  • G12d · 94 shared documents · no page of its own yet
  • Pancreatic Cancer · 88 shared documents · no page of its own yet
  • Immunotherapy · 69 shared documents
  • Kras-Mutant · 65 shared documents · no page of its own yet
  • Overall Survival · 65 shared documents · no page of its own yet
  • Egfr · 50 shared documents
  • Braf · 38 shared documents
  • Solid Tumors · 33 shared documents · no page of its own yet

Story momentum

Fading

The word compares 9 mentions on 2 Nov 2026 with 23 on 11 Oct 2026 (-61%); a change of less than 8% either way reads Steady.

Daily mentions -47% from 18 Sept 2026 to 2 Nov 2026, between 5 and 42 a day

How often tracked coverage mentions KRAS, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about KRAS yet. Ask about KRAS

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/7e334b5071e5b4486106b1fd returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name kras.

{
  "name": "kras",
  "label": "KRAS",
  "asOf": "2026-11-03",
  "mentions": 138,
  "outlets": 98,
  "domains": 13,
  "node": {
    "id": "sb:e/7e334b5071e5b4486106b1fd",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/7e334b5071e5b4486106b1fd",
    "knowledgeCutoff": "2026-11-03T13:08:56.552092+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "fading",
  "history": {
    "since": "2026-10-21T13:12:56.354446+00:00",
    "changes": 0
  },
  "whereFrom": {
    "level": "counts",
    "label": "138 mentions across 13 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "13 coverage domains",
        "children": {
          "count": 13,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 132 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving KRAS

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer - Oncodaily

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher

    could not check

  • KRAS in pancreatic cancer: from molecular biology to transformative therapeutics

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

    could not check

Walk the record from KRAS

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

KRAS

Entity.

Evidence
515 documents · 184 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 11 Mar 2026, last seen 2 Nov 2026
Measured
8% of mentions say something specific about it; the rest only name it
As of
3 Nov 2026
12 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (2)

  • Could not check: We could not count this claim's sources, so we do not say how well it is supported.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What it connects to

Related records.

Recorded history

No change in coverage state or wire tier recorded since 21 Oct 2026.

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 3 Nov 2026.